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Edited by Beat ImhofAbstract In eukaryotic cells, peroxiredoxins are both antioxi-
dants and regulators of H2O2-mediated signaling. We previously
found that peroxiredoxin-I (Prx-I) was overexpressed in non-
small cell lung cancer (NSCLC) tissue. Since overexpressed pro-
tein can induce a humoral immune response, we examined
whether serum from NSCLC patients exhibited immunoreactiv-
ity against Prx-I using Western blotting. We found that 25
(47%) of 53 NSCLC patients tested had autoantibodies against
Prx-I in their sera, whereas such activity was detected in 4 (8%)
sera from 50 healthy subjects. Prx-I itself was detected in the
sera from 18 (34%) of 53 NSCLC patients but in only 1 (2%)
serum from 50 controls. Moreover, 17% of NSCLC sera were
positive to both Prx-I antibody and antigen but none in control
sera. The data indicate both Prx-I autoantibody and circulating
antigen are potential biomarkers for use in serological diagnosis
of NSCLC. Interestingly enough, we found that Prx-I was se-
creted by lung adenocarcinoma cells (A549) but not by non-can-
cer lung cells (BEAS 2B) or breast cancer cells (MCF7). This
cell culture study suggests the possibility of Prx-I secretion from
NSCLC tumor tissues.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Lung cancer is the leading cause of cancer death [1] and
its prevention is a major worldwide challenge. At present,
diagnosis of lung cancer mainly relies on physical examina-
tion. By the time a physician discovers malignant tissue in
the lung, it is likely to contain at least one billion cancer
cells with high probability of metastasis, which underlies
the high mortality rate for this disease [2]. Therefore, there
is much interest in identifying biomarkers for early detection
of lung cancer [3,4]. A number of tumor antigens have been
evaluated as biomarkers, including a-fetoprotein, neuron-Abbreviations: Prx, peroxiredoxin; 2-DE, two-dimensional electropho-
resis; NSCLC, non-small cell lung cancer
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doi:10.1016/j.febslet.2005.04.028speciﬁc enolase (NSE), carcinoembryonic antigen (CEA),
cytokeratin 19 fragment (CYFRA 21-1), squamous cell car-
cinoma (SCC) antigen, cancer antigen 125 (CA125) and tis-
sue polypeptide antigen [5–11]. Autoantibodies against
several tumor antigens such as p53, embryonic neural pro-
teins and antineural/antinuclear antigens have also been
tested [12–15]. Recently, autoantibodies against PGP9.5, an-
nexin-I and annexin-II were found in the sera of lung cancer
patients using a proteomics approach [16,17]. However,
expression of these molecules does not appear to be suﬃ-
ciently sensitive and speciﬁc enough to be reliable for early
diagnosis. At present, great eﬀorts are being made in order
to discover better biomarkers for the earliest possible diag-
nosis of lung cancer.
We previously found that peroxiredoxin-I (Prx-I) is overex-
pressed in non-small cell lung cancer (NSCLC) tissue [18], and
other groups have presented similar data [19–21]. Prx-I is one
of six members of the Prx family, which are recently discovered
enzymes with antioxidant function [22,23]. Cancer cells may
become resistant to reactive oxygen species (ROS) stress
through Prx-I overexpression.
Although the mechanism underlying autoantibody genera-
tion is not fully understood, protein overexpression may
trigger a humoral autoimmune response [24–26]. In the pres-
ent study, Western blot analysis was used to screen sera
from cancer patients for the presence of autoantibodies that
react against Prx-I. We found that 25 (47%) of 53 NSCLC
patients had autoantibodies against Prx-I in their sera. In
addition, Prx-I antigen itself was detected in 18 (34%) out
of 53 sera from NSCLC patients. Meanwhile, 4 and 1 sera
from 50 controls were detected as Prx-I antibody and anti-
gen positives, respectively. Based on these ﬁndings, we pro-
pose that Prx-I is an autoimmunogenic human tumor
antigen of NSCLC.2. Materials and methods
2.1. Subjects
Tumor tissues and sera were collected at the Chonnam National
University Medical School Hospital (Gwangju, Korea). Sera from 53
lung cancer patients were obtained at the time of diagnosis after in-
formed consent. Patients comprised 34 males and 19 females with an
age range of 44–81 years (median, 63.8 years). The diagnoses were ade-
nocarcinoma (28 patients) and squamous carcinoma (25 patients).
Healthy controls comprised 31 males and 19 females with an age range
of 44–85 years (median, 64.8 years).blished by Elsevier B.V. All rights reserved.
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The human cell lines BEAS 2B (non-cancer lung cells), A549 (lung
adenocarcinoma cells) and MCF7 (breast cancer cells) were obtained
from the American Type Culture Collection. Cells were grown in
RPMI 1640 supplemented with 10% fetal bovine serum at 37 C under
a humidiﬁed atmosphere of 95% air and 5% CO2 (v/v). Cultured cells
were harvested when 90% conﬂuent after washing twice with phos-
phate-buﬀered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, and 2 mMKH2PO4, pH 7.4). To obtain conditioned media,
once cells were 70% conﬂuent they were cultured in serum-free medium
(3 ml per 60 mm dish culture), which was then collected at the indi-
cated times.
2.3. Immunohistochemical staining
Tissues were ﬁxed with 4% formaldehyde in PBS at 4 C overnight,
dehydrated with ethanol and penetrated with 100% xylene. Tissues
were coated with pre-warmed paraﬃn for 1 h and sliced using a micro-
tome. After removal of excessive paraﬃn with xylene and ethanol, tis-
sues were incubated in 1% BSA for 1 h and then with anti-Prx-I
antibody (LabFrontier, Seoul, Korea) overnight. After incubation with
secondary anti-rabbit antibody, immunoreactivity was determined by
the AEC method (streptavidin–biotin) using a DAKO kit (DAKO,
Carpinteria, CA). Tissues were counterstained with Mayers hematox-
ylin for nuclei staining.
2.4. Polyacrylamide gel electrophoresis (PAGE)
Protein samples were incubated with SDS sample buﬀer (60 mM
Tris, pH 6.8, 2% SDS, 10% glycerol, 5% b-mercaptoethanol, and
0.1% bromophenol blue) at 95 C for 5 min and then subjected to
SDS–PAGE using the method of Laemmli [27]. For two-dimensional
electrophoresis (2-DE), harvested cells were directly disrupted in urea
lysis buﬀer (9 M urea, 2% Chaps, 1% DTT, and 0.8% (v/v) carrier
ampholytes), centrifuged at 100000 · g at 4 C for 1 h and total pro-
tein was recovered in the supernatant. Immobilized pH gradient
(IPG) strips were prepared using the procedures described by Go¨rg
et al. [28] and 2-DE was performed as previously described [18].
Brieﬂy, samples were applied to the IPG strips during rehydration in
IPGphor (Pharmacia) and electrophoresed at 20 V for 12 h. Proteins
then underwent isoelectric focusing (IEF) using the following voltage
sequence: 500 V for 1 h, 1000 V for 1 h, a gradual increase over 1 h
to 8000 V, and ﬁnally 8000 V for 1 h. After IEF, IPG strips were incu-
bated for 15 min in 50 mM Tris, pH 8.8, 6 M urea, 30% glycerol, 2%
SDS, and 1% DTT, and then for an additional 15 min in the same solu-
tion containing 2.5% iodoacetamide instead of DTT. The strips were
then placed on 10–16% gradient polyacrylamide gels and electrophore-
sis was performed at 120 V in 25 mM Tris, pH 8.8, 192 mM glycine,
and 0.1% SDS. The protein concentration was determined using the
Bradford method [29].2.5. Western blotting
Proteins separated by 1-DE or 2-DE were transferred to nitrocellu-
lose membranes, which were incubated for 2 h with 5% (w/v) non-fat
dry milk in TBS–T (25 mM Tris, pH 7.5, 150 mM NaCl, and 0.05%
(w/v) Tween-20). After washing with TBS-T, membranes were incu-
bated for 1 h with 2000-fold diluted anti-Prx-I or anti-Prx-IV antibody
(LabFrontier, Seoul, Korea) or diluted sera (1:500). Membranes were
then washed with TBS-T and incubated with horseradish peroxidase-
conjugated anti-rabbit secondary antibody (1:5000) (Jackson Immuno-Fig. 1. Overexpression of Prx-I in malignant lung tissue. Normal (A) and can
using an anti-Prx-I antibody. Arrows indicate strongly Prx-I-positive cells
B = 100· magniﬁcation. C = 200· magniﬁcation.Research Laboratories Inc., West Grove, PA) or anti-human second-
ary antibody (1:5000) (Amersham Bioscience, Uppsala, Sweden).
Immunoreactive proteins were detected using ECL reagents.
2.6. Preparation of hexahistidine-tagged peroxiredoxin-I (H6Prx-I)
The Prx-I gene was ampliﬁed from a human lung cDNA library
(Clontech, Palo Alto, CA) by polymerase chain reaction using the
following primers: 5 0-ggatccgcgatgtcttcaggaaatgc-3 0 and 5 0-
cccaagcttggtcacttctgcttggag-3 0. Ampliﬁed DNA fragments were ligated
between the BamHI and HindIII sites of the pET28a vector (Novagen,
Darmstadt, Germany) to create a pET28/H6Prx-I, and this plasmid
was transformed into BL21(DE3) E. coli. Recombinant H6Prx-I
protein was expressed following induction with 1 mM isoprophy-b-
D-thiogalactoside, and puriﬁed by aﬃnity chromatography using a
Ni–nitrilotriacetic acid column (Novagen).
2.7. Mass spectrometry
Protein spots in Coomassie blue-stained gels were identiﬁed by pep-
tide mass ﬁngerprinting (PMF) using matrix assisted laser desorption/
ionization-time of ﬂight (MALDI-TOF) mass spectrometry as de-
scribed previously [18]. Proteins in conditioned media were digested
with modiﬁed trypsin (Promega, Madison, WI) and analyzed using
tandem mass spectrometry directly connected with biphasic microcap-
illary chromatography (LC/LC_MS/MS). Brieﬂy, the digested product
was acidiﬁed and injected on to a biphasic microcapillary HPLC col-
umn. The ﬁrst phase contained 4 cm of Partisphere strong-cation ex-
change media (Whatman, Clifton, NJ) and the second phase
contained 7 cm of reversed-phase Polaris C18-A 5 lm resin (Phenom-
enex, Torrance, CA). Peptides eluted from the capillary column were
electrosprayed into a LCQ Deca XP ion trap mass spectrometer (Ther-
moFinnigan, Woburn, MA). Bioworks Ver 3.1 was used to ﬁlter the
search results.3. Results
3.1. Prx-I is overexpressed in NSCLC tissue
Our previous proteome analysis comparing A549 lung can-
cer and BEAS 2B lung non-cancer cells showed that Prx-I
was overexpressed in A549 cells, and subsequent Western blot-
ting showed that Prx-I was also overexpressed in malignant
lung tissue from NSCLC patients [18]. In the present study,
we used immunohistochemical methods to compare Prx-I
expression between malignant and non-malignant lung tissue
sampled from the same NSCLC patient. We found that
Prx-I was more highly expressed in cancer tissues (Fig. 1).
Interestingly enough, relatively higher expression of Prx-I
was frequently observed in cells exposed to airways or in
peripheral cells of the cancer mass (arrows in Fig. 1B and C).
3.2. Autoantibodies against Prx-I are present in NSCLC patient
sera
Given the increased expression of Prx-I in NSCLC patient
cancer tissue, we investigated whether NSCLC patient seracer (B and C) tissue from the same NSCLC patient was immunostained
located near airways or on the periphery of the cancer mass. A and
Fig. 2. Prx-I autoantibodies in serum from NSCLC patients. (A) Total protein extracts from A549 cells were separated by 2-DE and stained with
Coomassie blue. The protein spot indicated by the arrow was identiﬁed as Prx-I using peptide mass ﬁngerprinting. (B) An enlargement of the region
containing the Prx-I protein (box in panel A). A549 cell lysate proteins were separated by 2-DE, transferred to nitrocellulose membranes and then
immunoblotted with either an anti-Prx-I antibody (1:2000) (C), or with diluted (1:500) sera combined from 10 healthy control subjects (D) or 10
NSCLC patients (E). Membranes were then incubated with appropriate secondary antibodies and data visualized using chemiluminescence.
Fig. 3. Prx-I autoantibodies and antigen in serum from NSCLC
patients. (A) Puriﬁed recombinant H6Prx-I (5, 10, 20 and 40 ng) was
Western blotted and probed with combined sera from 10 healthy
controls or 10 NSCLC patients. (B) H6Prx-I (10 ng) was Western
blotted and probed with individual serum from healthy control
subjects and NSCLC patients. (C) Individual serum (10 ll) from
healthy control subjects and NSCLC patients was Western blotted and
probed with an anti-Prx-I antibody. Results from 20 sera from patients
or controls were shown as the representative data in B and C.
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jected to 2-DE (Fig. 2A), and the position to which Prx-I mi-
grated (arrows in Fig. 2B) was conﬁrmed by MALDI-TOF
mass spectrometry (data not shown) and Western blotting with
an anti-Prx-I antibody (Fig. 2C). To determine whether
NSCLC patient sera contained Prx-I autoantibodies, A549 cell
lysates were subjected to 2-DE, transferred to membranes,
incubated with pooled sera from 10 healthy control subjects
or 10 NSCLC patients, and immunoreactive spots identiﬁed.
We found that an antibody present in lung cancer patient sera
reacted with Prx-I (Fig. 2E), while no such reaction was ob-
served with healthy sera (Fig. 2D). These data indicate that
lung cancer patient sera contain autoantibodies against
Prx-I. We then screened individual patient serum for Prx-I
autoantibodies. Puriﬁed, recombinant Prx-I with hexahistidine
at the N-terminus (H6Prx-I) was Western blotted and probed
with individual patients serum. We found that the combined
patient sera used above was able to detect as low as 5 ng
H6Prx-I whereas the control sera could not detect 40 ng
H6Prx-I (Fig 3A). Individual analysis against 10 ng H6Prx-I
showed that sera from 25 (47%) of the 53 NSCLC patients
contained immunoreactivity, whereas 4 (8%) positive signals
were detected from age- and sex-matched 50 control sera
(Fig. 3B and Table 1). We also examined whether Prx-I antigen
itself was circulating in sera from NSCLC patients. By Wes-
tern blot analysis using Prx-I antibody, Prx-I was detected in
sera from 18 (34%) of the 53 patients, whereas it was detected
in only 1 out of the 50 healthy control sera (Fig. 3C and Table
1). Although the number of subjects is not enough to deter-
mine any diﬀerences in Prx-I antibody and antigen positives
among cancer types and stages (Table 1), the data strongly
suggest that both Prx-I antibody and antigen are potential bio-
markers for use in serological diagnosis of NSCLC.
3.3. Secretion of Prx-I from A549 cells
The detection of Prx-I in patient sera was somewhat unex-
pected since this protein is known to be cytosolic and has no
signal peptide [23]. We examined whether Prx-I was secreted
from cultured lung cancer cells. Fresh media was placed on
BEAS 2B (human lung non-cancer) and A549 (human lung
cancer) cells, and was then collected after 1, 2, 4 and 8 h and
analyzed by Western blotting using an anti-Prx-I antibody.
Prx-I was detected in A549-conditioned media but not in
BEAS 2B-conditioned media (Fig. 4A). In addition, Prx-Iwas not detected in media conditioned by MCF7 breast cancer
cells (Fig. 4B). Among Prx family members, only Prx-IV has a
signal sequence and a potential to be secreted [30,31]. We did
not detect Prx-IV in A549-conditioned media by Western blot-
ting using an anti-Prx-IV antibody (data not shown). The pres-
ence of Prx-I in A549-conditioned media was conﬁrmed by
LC/LC_MS/MS analysis (Fig. 4C), while any other Prxs
including Prx-IV were not detected by this analysis.4. Discussion
We previously found that Prx-I is overexpressed in NSCLC
tissue [18], and Prx-I overexpression in lung cancer has also
Fig. 4. Secretion of Prx-I from A549 cells. (A) Conditioned media
from cultured BEAS 2B and A549 cells were collected at the indicated
times and analyzed by Western blotting using an anti-Prx-I antibody.
(B) Conditioned media from cultured BEAS 2B, A549, and MCF7
cells were collected at 8 h and analyzed by Western blotting with the
same antibody. Prx-I and tubulin in cell lysates were monitored by
Western blot analyses (A and B). (C) Prx-I in A549-conditioned
medium was conﬁrmed by tandem mass spectrometry. Asterisks
indicate Prx-I-speciﬁc amino acids comparing to Prx-IV.
Table 1
Prx-I Ab and Ag positive sera from NSCLC patients and control subjects
Number of subjects Prx-I Ab positive Prx-I Ag positive Prx-I Ab/Ag positive
Non-small cell lung cancer 53 25 (47.1) 18 (33.9) 9 (17.0)
Types
Adenocarcinoma 28 14 (50.0) 10 (35.7) 5 (17.9)
Squamous carcinoma 25 11 (44.0) 8 (32.0) 4 (16.0)
Stages
I/II 12 4 (33.3) 3 (25.0) 0 (0)
III 20 12 (60.0) 6 (30.0) 4 (20.0)
IV 21 9 (42.9) 9 (42.9) 5 (23.8)
Controls 50 4 (8.0) 1 (2.0) 0 (0)
Numbers in parentheses are percentage. Ab, antibody; Ag, antigen.
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I expression may have an important role in oncogenic transfor-
mation of human lung cells. Prx-I overexpression may protect
cancer cells from oxidative stress, which may increase cell sur-
vival [32]. Therefore, down-regulation of Prx-I may improve
outcomes of lung cancer therapy.
Many biomarkers have been suggested and evaluated for
early diagnosis of lung cancer [5–17]. However, they are not
routinely used clinically because their sensitivity and speciﬁcity
are not high enough. While some groups have used several bio-
markers in combination in attempts to improve speciﬁcity andsensitivity, there is still a great need for better early diagnosis
biomarkers of lung cancer.
Although it is not clear why some patients develop immu-
nogenicity to a particular antigen, the majority of tumor-
associated antigens are not products of mutated genes but
are overexpressed proteins or antigens related to cell diﬀer-
entiation [24–26]. The present study demonstrated the pres-
ence of Prx-I autoantibodies and antigen in NSCLC
patient serum. Although we screened only 53 sera from can-
cer patients, the frequency with which these proteins were
identiﬁed (47% for antibody and 35% for antigen) is high
enough to consider Prx-I as a potential clinical biomarker
of NSCLC.
Over 80% of lung cancer patients suﬀer from NSCLC, which
represents a mixed group of tumors with diﬀering histology,
clinical course and response to treatment. The heterogeneous
nature of NSCLC limits the use of biomarkers. Cancer typing
can improve diagnosis because biomarkers speciﬁc to certain
cancer types will improve sensitivity and speciﬁcity. Recently,
proteomics approaches provided a novel method for lung can-
cer typing [33,34]. Levels of Prx-I overexpression can be used
as a criterion for NSCLC typing.
We found that despite a lack of signal peptide, Prx-I was
secreted by A549 lung cancer cells. Prx-I secretion was also
reported from cultured astrocyte cells [35]. Furthermore,
PGP9.5, which does not have signal peptide, was also shown
to be secreted from A549 cells [16]. However, Prx-I overexpres-
sion per se does not appear to cause secretion since there was
no Prx-I secretion from MCF7 cells, which also overexpress
Prx-I. We are currently investigating the mechanisms involved
in Prx-I secretion from A549 cells and its functional relevance
in lung cancers.
Our ﬁndings indicate that overexpressed Prx-I in NSCLC in-
duces a humoral immune response and suggest that Prx-I
autoanitbody and antigen are potential biomarker for clinical
serological screening of lung cancer.
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